Australia Breast Lesion Localization Methods Market

Market Overview

The Australia breast lesion localization methods market size has witnessed significant growth in the past and is expected to grow at a CAGR of 16.5% during the forecast period (2022–2031).

The acceptance and usage of breast lesion localization methods, including MRI, ultrasound, and mammography, is contingent upon the healthcare infrastructure of the specific healthcare systems.

Market Dynamics

Australia Breast Lesion Localization Methods Market Drivers

Surge in Health Insurance Enrollment

The exorbitant expenses of cancer treatment present a significant barrier to the market's growth. However, there has been a notable increase in individuals' adoption of healthcare insurance plans. These countries offer some of the most affordable healthcare insurance options worldwide. As a result, access to health insurance coverage has improved, alleviating concerns about the financial implications of cancer treatment. This, in turn, encourages more individuals to seek the expertise of oncologists, knowing that the financial burden will be somewhat relieved.

Australia Breast Lesion Localization Methods Market Restraint

Lack of Sufficient Oncology Facilities

Adequate availability of skilled oncologists is crucial for successfully diagnosing, treating, and caring for cancer patients. However, there is a significant shortage of proficient oncologists delivering comprehensive, high-quality care. Moreover, access to advanced localization technology is predominantly limited to developed countries, mainly due to inadequate healthcare infrastructure in other regions. Furthermore, many hospitals that provide oncology services lack the necessary equipment and technologies for the precise diagnosis and treatment of breast cancer.

Australia Breast Lesion Localization Methods and Market Opportunities

Attractive Market Potential in Developing Nations

The rapid urbanization in these countries has led to a significant influx of people into urban areas, necessitating government and private entities' expansion of healthcare infrastructure. Our research reveals that government hospitals in these regions lack technology and resources, prompting private hospitals to invest heavily in advanced equipment to attract more patients and capitalize on the gap in public healthcare services. Additionally, the governments are offering incentives, such as affordable or free land, patient-based incentives, subsidies for treatment costs, and easy access to loans for machinery procurement, to encourage the establishment of new hospitals. Consequently, numerous private players are constructing new hospitals and expanding their networks to establish their brands and strengthen their market position.

Regional Analysis

Australia's breast lesion localization methods market has grown significantly in recent years. The country has a well-developed healthcare infrastructure and advanced medical facilities. Awareness and early detection initiatives have increased the demand for breast lesion localization methods. The adoption of advanced imaging technologies, such as mammography, ultrasound, and MRI, is prevalent, ensuring accurate diagnosis and effective treatment of breast cancer.

Segmental Analysis

The Australian breast lesion localization methods market is segmented into type and usage.

By Type it is further segmented into wire localization, radioisotope localization, magnetic localization, and others.

Wire localization dominated the market and is expected to register a CAGR of 16.9% over the forecast period. Wire localization is used to identify the lesion's exact location, which aids the surgeon in detecting and removing breast lesions without difficulty if the X-ray detects multiple lesions. This method removes lesions or tumors that are difficult to locate and cannot be felt. In addition, it can be used to remove the smallest possible area, which would be difficult for the surgeon to do without causing visible harm to the surrounding tissue. Some women may experience vertigo or pressure during the painless procedure.

It is further segmented based on usage into tumor identification and sentinel lymph node identification.

Tumor identification dominated the market and is expected to register a CAGR of 16.1% over the forecast period. A triple test is administered for tumor identification, including a physical examination, breast imaging, mammography, and a biopsy. The majority of patients are breast cancer patients. Mammography involves using X-rays to image a breast region containing a tumor. Other imaging technologies, such as MRI and ultrasound, are also employed. Ultrasound is predominantly recommended for women under 30 years old.

Recent Developments

• January 2021: Hologic, Inc., an innovative medical technology company focused on improving women’s health, announced and completed the acquisition of SOMATEX Medical Technologies GmbH, a leader in biopsy site markers and localization technologies, for approximately USD 64 million. The company was previously owned by E-Med Solutions GmbH, Berlin, a group of investors led by German private equity company Westlake Partners.